Therapy-related acute myeloid leukemia with minimal myeloid differentiation (AML-M0) associated with a t(11;19)(q23;p13.3) translocation

Am J Hematol. 1997 Jul;55(3):165-6. doi: 10.1002/(sici)1096-8652(199707)55:3<165::aid-ajh10>3.0.co;2-c.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Small Cell / drug therapy
  • Chromosomes, Human, Pair 11*
  • Cyclophosphamide / therapeutic use
  • DNA-Binding Proteins / genetics
  • Doxorubicin / therapeutic use
  • Gene Rearrangement / drug effects
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Leukemia, Myeloid, Acute / chemically induced*
  • Leukemia, Myeloid, Acute / genetics
  • Lung Neoplasms / drug therapy
  • Male
  • Myeloid-Lymphoid Leukemia Protein
  • Podophyllotoxin / adverse effects*
  • Podophyllotoxin / therapeutic use
  • Proto-Oncogenes*
  • Transcription Factors*
  • Translocation, Genetic*
  • Vincristine / therapeutic use
  • Zinc Fingers

Substances

  • Antineoplastic Agents, Phytogenic
  • DNA-Binding Proteins
  • KMT2A protein, human
  • Transcription Factors
  • Myeloid-Lymphoid Leukemia Protein
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Histone-Lysine N-Methyltransferase
  • Podophyllotoxin

Supplementary concepts

  • EVAC protocol